M
Massimo Libra
Researcher at University of Catania
Publications - 318
Citations - 18535
Massimo Libra is an academic researcher from University of Catania. The author has contributed to research in topics: Cancer & PI3K/AKT/mTOR pathway. The author has an hindex of 64, co-authored 296 publications receiving 15175 citations. Previous affiliations of Massimo Libra include East Carolina University.
Papers
More filters
Journal ArticleDOI
Roles of the raf/mek/erk pathway in cell growth, malignant transformation and drug resistance
James A. McCubrey,Linda S. Steelman,William H. Chappell,Stephen L. Abrams,Ellis W.T. Wong,Fumin Chang,Brian D. Lehmann,David M. Terrian,Michele Milella,Agostino Tafuri,Franca Stivala,Massimo Libra,Jörg Bäsecke,Camilla Evangelisti,Alberto M. Martelli,Richard A. Franklin +15 more
TL;DR: The Raf/MEK/ERK pathway has different effects on growth, prevention of apoptosis, cell cycle arrest and induction of drug resistance in cells of various lineages which may be due to the presence of functional p53 and PTEN and the expression of lineage specific factors.
Journal ArticleDOI
Roles of the RAF/MEK/ERK and PI3K/PTEN/AKT pathways in malignant transformation and drug resistance.
James A. McCubrey,Linda S. Steelman,Steven L. Abrams,John T. Lee,Fumin Chang,Fred E. Bertrand,Patrick M. Navolanic,David M. Terrian,Richard A. Franklin,A B D'Assoro,Jeffrey L. Salisbury,Maria Clorinda Mazzarino,Franca Stivala,Massimo Libra +13 more
TL;DR: The Ras/Raf/MEK/ERK and PI3K/PTEN/AKT signaling cascades play critical roles in the transmission of signals from growth factor receptors to regulate gene expression and prevent apoptosis and are commonly thought to have anti-apoptotic and drug resistance effects on cells, but they display different cell-lineage-specific effects.
Journal ArticleDOI
Roles of the Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR pathways in controlling growth and sensitivity to therapy-implications for cancer and aging
Linda S. Steelman,William H. Chappell,Stephen L. Abrams,C. Ruth Kempf,Jacquelyn M. Long,Piotr Laidler,Sanja Mijatović,Danijela Maksimović-Ivanić,Franca Stivala,Maria Clorinda Mazzarino,Marco Donia,Paolo Fagone,Graziella Malaponte,Ferdinando Nicoletti,Massimo Libra,Michele Milella,Agostino Tafuri,Antonio Bonati,Jörg Bäsecke,Lucio Cocco,Camilla Evangelisti,Alberto M. Martelli,Giuseppe Montalto,Melchiorre Cervello,James A. McCubrey +24 more
TL;DR: The functions these pathways have in normal and neoplastic tissue growth and how they contribute to resistance to apoptotic stimuli are discussed and the recently described roles of these pathways in cancer stem cells, cellular senescence and aging are evaluated.
Journal ArticleDOI
Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR Inhibitors: Rationale and Importance to Inhibiting These Pathways in Human Health
William H. Chappell,Linda S. Steelman,Jacquelyn M. Long,Ruth C. Kempf,Stephen L. Abrams,Richard A. Franklin,Jörg Bäsecke,Franca Stivala,Marco Donia,Paolo Fagone,Graziella Malaponte,Maria Clorinda Mazzarino,Ferdinando Nicoletti,Massimo Libra,Danijela Maksimović-Ivanić,Sanja Mijatović,Giuseppe Montalto,Melchiorre Cervello,Piotr Laidler,Michele Milella,Agostino Tafuri,Antonio Bonati,Camilla Evangelisti,Lucio Cocco,Alberto M. Martelli,James A. McCubrey +25 more
TL;DR: This review will evaluate more recently described potential uses of MEK, PI3K, Akt and mTOR inhibitors in the proliferation of malignant cells, suppression of CICs, cellular senescence and prevention of aging.
Journal ArticleDOI
Evolution of Cancer Pharmacological Treatments at the Turn of the Third Millennium.
TL;DR: Today, cancer research is always aimed at the study and development of new therapeutic approaches for cancer treatment, and several researchers are focused on the development of cell therapies, anti-tumor vaccines, and new biotechnological drugs that have already shown promising results in preclinical studies, therefore, in the near future, it will certainly assist to a new revolution in the field of medical oncology.